原站：http://www.nature.com/nrd/current_issue/

指数：

“Nature Reviews Drug Discovery - Issue - nature.com s”的内容更新

累计：700 篇（自 2007-05-21 起）

更新：约3篇/周，最后更新16 天前

Nature Reviews Drug Discovery - Issue - nature.com science feeds

In this issue

in this issuenature reviews drug discovery 11, 87 (2012). doi:10.1038/nrd3658recent advances in rna biology have accelerated the progress of a new generation of molecular therapies based on rna, with several agents now in advanced clinical trials. in our first review, kole and colleagues compare and contrast the mechanisms of action and effects o... (16 天前)

http://inezha.com/w/93m3ooxs

Nature Reviews Drug Discovery - Issue - nature.com science feeds

(Mis)treating the pharmacogenetic incidentalome

(mis)treating the pharmacogenetic incidentalomenature reviews drug discovery 11, 89 (2012). doi:10.1038/nrd3659author: isaac s. kohanegenome-wide screening is anticipated to accelerate the development of personalized medicine by identifying and exploiting new associations between genomic variants and drug responses. however, this goal could be u... (16 天前)

http://inezha.com/w/bvwlxoxc

Nature Reviews Drug Discovery - Issue - nature.com science feeds

2011 FDA drug approvals

2011 fda drug approvalsnature reviews drug discovery 11, 91 (2012). doi:10.1038/nrd3657author: asher mullardthe us fda approved 30 new therapeutics last year, including 11 first-in-class agents.... (16 天前)

http://inezha.com/w/t5dyg3x3

Nature Reviews Drug Discovery - Issue - nature.com science feeds

News in brief

news in briefnature reviews drug discovery 11, 95 (2012). doi:10.1038/nrd3666globalization of clinical trials plateaus?the off-shoring of clinical trials outside the united states and europe may have hit a plateau.the lowdown: over the past decade, drug sponsors have increasingly shifted clinical trial programmes from the united states and europe... (16 天前)

http://inezha.com/w/xxmze3xr

Nature Reviews Drug Discovery - Issue - nature.com science feeds

Deal watch: Abbott boosts investment in NRF2 activat

deal watch: abbott boosts investment in nrf2 activators for reducing oxidative stressnature reviews drug discovery 11, 96 (2012). doi:10.1038/nrd3655author: sarah crunkhornin one of the largest preclinical-stage deals ever, abbott has agreed to pay us$400 million upfront to reata pharmaceuticals as part of an agreement to jointly develop and com... (16 天前)

http://inezha.com/w/y8w9q3xh

Nature Reviews Drug Discovery - Issue - nature.com science feeds

Trial watch: BTK inhibitor shows positive results in

trial watch: btk inhibitor shows positive results in b cell malignanciesnature reviews drug discovery 11, 96 (2012). doi:10.1038/nrd3656author: charlotte harrisonpreliminary clinical trial data recently presented at the american society of hematology meeting showed that the bruton's tyrosine kinase (btk) inhibitor pci-32765 was effective in trea... (16 天前)

http://inezha.com/w/0rh693xz

Nature Reviews Drug Discovery - Issue - nature.com science feeds

Patent watch

patent watchnature reviews drug discovery 11, 98 (2012). doi:10.1038/nrd3667author: charlotte harrisonregeneron and genentech's vegf trap dispute settles... and continues regeneron and genentech have settled their patent dispute over eylea (aflibercept) — a treatment for wet age-related macular degeneration — which was launched onto the us mar... (16 天前)

http://inezha.com/w/egzko3xx

订阅者 ( 6 )

相关订阅源